Rare, unusual, and less common virus infections after organ transplantation

Current Opinion in Organ Transplantation

Volumn 16, Issue 6, 2011, Pages 580-587

  Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

arenavirus; bocavirus; Kaposi's sarcoma; lymphocytic choriomeningitis virus; parvovirus; rabies; West Nile virus

Indexed keywords

BLEOMYCIN; CIDOFOVIR; CYTARABINE; DOXORUBICIN; FOSCARNET; GANCICLOVIR; HEPATITIS VACCINE; IMMUNOGLOBULIN; INTERFERON; KETAMINE; MIDAZOLAM; PHENOBARBITAL; RABIES VACCINE; RAPAMYCIN; RIBAVIRIN; VALGANCICLOVIR; VIDARABINE; VINCRISTINE; ZALCITABINE;

ADENOVIRUS; ADENOVIRUS INFECTION; ALLOTRANSPLANTATION; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARENAVIRUS INFECTION; BK VIRUS; BOCAVIRUS; BOCAVIRUS INFECTION; BRONCHITIS; CHRONIC HEPATITIS; COLITIS; CONJUNCTIVITIS; DIARRHEA; ERYTHEMA INFECTIOSUM; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEPATITIS; HEPATITIS E VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN PARVOVIRUS B19; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTOPENIA; PNEUMONIA; POLYOMA VIRUS; POLYOMAVIRUS INFECTION; PRIMARY EFFUSION LYMPHOMA; RABIES; RABIES VIRUS; REVIEW; RHINORRHEA; STEM CELL TRANSPLANTATION; VIREMIA; VIRUS ENCEPHALITIS; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ANTIVIRAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PROGNOSIS; RARE DISEASES; RISK ASSESSMENT; RISK FACTORS; VIRUS DISEASES;

EID: 81255161626     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834cdaf2     Document Type: Review

References (76)

1. Razonable RR, Eid AJ. Viral infections in transplant recipients. Minerva Med 2009; 100:479-501.
2. Razonable RR. Management of viral infections in solid organ transplant recipients. Expert Rev Anti Infect Ther 2011; 9:685-700.
3. Ison MG, Green M. Adenovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S161-S165.
4. Humar A, Kumar D, Mazzulli T, et al. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant 2005; 5:2555-2559.
5. Watcharananan SP, Avery R, Ingsathit A, et al. Adenovirus disease after kidney transplantation: course of infection and outcome in relation to blood viral load and immune recovery. Am J Transplant 2011; 11:1308-1314.
6. Pinchoff RJ, Kaufman SS, Magid MS, et al. Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation 2003; 76:183-189. (Pubitemid 36877134)
7. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100:1619-1627. (Pubitemid 34925137)
8. McGrath D, Falagas ME, Freeman R, et al. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance. J Infect Dis 1998; 177:459-462. (Pubitemid 28063775)
9. Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001; 344:1498-1503. (Pubitemid 32429208)
10. Echavarria M, Forman M, van Tol MJ, et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358:384-385. (Pubitemid 32739102)
11. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43:331-339. (Pubitemid 44078906)
12. Charrel RN, de Lamballerie X. Zoonotic aspects of arenavirus infections. Vet Microbiol 2010; 140:213-220.
13. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006; 354:2235-2249. (Pubitemid 43788138)
14. CDC. Brief report: lymphocytic choriomeningitis virus transmitted through solid organ transplantation - Massachusetts, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:799-801.
15. Allander T, de Lamballerie X, Simmonds P. A new arenavirus in transplantation. N Engl J Med 2008; 358:2638. (Pubitemid 351831368)
16. Khuroo MS, Khuroo MS. Hepatitis E virus. Curr Opin Infect Dis 2008; 21:539-543.
17. Kamar N, Mansuy JM, Cointault O, et al. Hepatitis E virus-related cirrosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 2008; 8:1744-1748.
18. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358:811-817. (Pubitemid 351281642)
19. Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009; 15:1225-1228.
20. Haagsma EB, van den Berg AP, Porte RJ, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008; 14:547-553. (Pubitemid 351524412)
21. le Coutre P, Meisel H, Hofmann J, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut 2009; 58:699-702.
22. Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis 2011; 17:30-37.
23. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140:1481-1489.
24. Pischke S, Wedemeyer H. Chronic hepatitis E in liver transplant recipients: a significant clinical problem? Minerva Gastroenterol Dietol 2010; 56:121-128.
25. Kamar N, Bendall RP, Peron JM, et al. Hepatitis E virus and neurologic disorders. Emerg Infect Dis 2011; 17:173-179.
26. Baylis SA, Hanschmann KM, Blumel J, Nubling CM. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol 2011; 49:1234-1239.
27. Khudyakov Y, Kamili S. Serological diagnostics of hepatitis E virus infection. Virus Res 2011; 161:84-92.
28. Kamili S. Toward the development of a hepatitis E vaccine. Virus Res 2011; 161:93-100.
29. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356:895-903. (Pubitemid 46339908)
30. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895-902.
31. Alric L, Bonnet D, Beynes-Rauzy O, Izopet J, Kamar N. Definitive clearance of a chronic hepatitis E virus infection with ribavirin treatment. Am J Gastroenterol 2011; 106:1562-1563.
32. Chaillon A, Sirinelli A, De Muret A, et al. Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation. J Heart Lung Transplant 2011; 30:841-843.
33. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology 2011; 139:1612-1618.
34. Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S97-S100.
35. Abdel Massih RC, Razonable RR. Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol 2009; 15:2561-2569.
36. Razonable RR, Lautenschlager I. Impact of human herpes virus 6 in liver transplantation. World J Hepatol 2010; 2:345-353.
37. Lee SO, Brown RA, Eid AJ, Razonable RR. Chromosomally integrated human herpesvirus-6 in kidney transplant recipients. Nephrol Dial Transplant 2011; 26:2391-2393.
38. Lee SO, Brown RA, Razonable RR. Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients. Transplantation 2011; 92:224-229.
39. Moore PS, Chang Y. Molecular virology of Kaposis sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 2001; 356:499-516. (Pubitemid 32442749)
40. Ariza-Heredia E, Razonable R. Human herpesvirus 8 in organ transplant recipients. Transplantation POST AUTHOR CORRECTIONS, 23 September 2011 doi: 10.1097/TP.0b013e31823104ec.
41. Qu L, Jenkins F, Triulzi DJ. Human herpesvirus 8 genomes and seroprevalence in United States blood donors. Transfusion 2010; 50:1050-1056.
42. Mbulaiteye SM, Engels EA. Kaposis sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer 2006; 119:2685-2691. (Pubitemid 44691326)
43. Moosa MR. Kaposis sarcoma in kidney transplant recipients: a 23-year experience. Qjm 2005; 98:205-214. (Pubitemid 40361318)
44. Stallone G, Infante B, Grandaliano G, et al. Kaposis sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. Transpl Int 2008; 21:825-832.
45. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87:157-163.
46. Boulanger E, Afonso PV, Yahiaoui Y, et al. Human herpesvirus-8 (HHV-8)- associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008; 8:707-710. (Pubitemid 351287542)
47. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198:23-30. (Pubitemid 351920285)
48. Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006; 43:40-48. (Pubitemid 43941646)
49. Allander T. Human bocavirus. J Clin Virol 2008; 41:29-33.
50. Pavia AT. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis 2011; 52 (Suppl 4):S284-S289.
51. Schenk T, Strahm B, Kontny U, et al. Disseminated bocavirus infection after stem cell transplant. Emerg Infect Dis 2007; 13:1425-1427. (Pubitemid 47510320)
52. Eid AJ, Posfay-Barbe KM. Parvovirus B19 in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S147-S150.
53. Broliden K. Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation. Pediatr Transplant 2001; 5:320-330. (Pubitemid 32834798)
54. Cassinotti P, Siegl G. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 2000; 19:886-887.
55. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005; 17:658-665. (Pubitemid 40558222)
56. Dumoulin A, Hirsch HH. Reevaluating and optimizing polyomavirus BK and JC real-time PCR assays to detect rare sequence polymorphisms. J Clin Microbiol 2011; 49:1382-1388.
57. Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998; 4:451-456. (Pubitemid 28395727)
58. Razonable RR, Aksamit AJ, Wright AJ, Wilson JW. Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Clin Proc 2001; 76:1171-1175. (Pubitemid 33032394)
59. Kusne S, Smilack J. Transmission of rabies virus from an organ donor to four transplant recipients. Liver Transpl 2005; 11:1295-1297. (Pubitemid 41511947)
60. Gode GR, Bhide NK. Two rabies deaths after corneal grafts from one donor. Lancet 1988; 2:791.
61. Houff SA, Burton RC, Wilson RW, et al. Human-to-human transmission of rabies virus by corneal transplant. N Engl J Med 1979; 300:603-604. (Pubitemid 9123120)
62. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005; 352:1103-1111. (Pubitemid 40365351)
63. Burton EC, Burns DK, Opatowsky MJ, et al. Rabies encephalomyelitis: clinical, neuroradiological, and pathological findings in 4 transplant recipients. Arch Neurol 2005; 62:873-882. (Pubitemid 40973449)
64. Maier T, Schwarting A, Mauer D, et al. Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin Infect Dis 2010; 50:1112-1119.
65. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348:2196-2203. (Pubitemid 36618130)
66. Kumar D, Prasad GV, Zaltzman J, et al. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004; 77:399-402. (Pubitemid 38209739)
67. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349:1236-1245. (Pubitemid 37152033)
68. Kiberd BA, Forward K. Screening for West Nile virus in organ transplantation: a medical decision analysis. Am J Transplant 2004; 4:1296-1301. (Pubitemid 39013576)
69. Kumar D, Humar A. Emerging viral infections in transplant recipients. Curr Opin Infect Dis 2005; 18:337-341. (Pubitemid 41017639)
70. Kumar D, Drebot MA, Wong SJ, et al. Humar A: a seroprevalence study of West Nile virus infection in solid organ transplant recipients. Am J Transplant 2004; 4:1883-1888. (Pubitemid 39434451)
71. Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol 2004; 61:1210-1220. (Pubitemid 39062673)
72. Shi PY, Wong SJ. Serologic diagnosis of West Nile virus infection. Expert Rev Mol Diagn 2003; 3:733-741. (Pubitemid 37428960)
73. Li S, Fang M, Zhou B, et al. Simultaneous detection and differentiation of dengue virus serotypes 1-4, Japanese encephalitis virus, and West Nile virus by a combined reverse-transcription loop-mediated isothermal amplification assay. Virol J 2011; 8:360.
74. Jordan I, Briese T, Fischer N, et al. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000; 182:1214-1217.
75. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002; 8:107-108. (Pubitemid 34094299)
76. Hofmeister Y, Planitzer CB, Farcet MR, et al. Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus. J Virol 2011; 85:1896-1899.